Close Menu

Breaking News

Interpace Diagnostics' ThyGeNext and ThyraMir thyroid cancer assays are now covered for about 2.5 million patients in Philadelphia and Southeastern Pennsylvania.

McKesson will be the exclusive distributor of the QiaStat-Dx system in US hospitals with fewer than 200 beds and non-exclusive distributor for future expansion into retail pharmacy clinics.

The new grant will be used to conduct whole-exome sequencing on 1,000 children participating in an autism spectrum disorder study for the purposes of biomarker development.

Genome-wide association analyses spanning 26 phenotypes in diverse populations revealed new risk variants and population-specific contributions for known SNPs.

The complaint alleges that NeuMoDx is willfully infringing on six BD-held patents, and demands injunctive relief, damages, and a jury trial.

Predictive Laboratories will use Thermo Fisher reproductive health products to research the genetic basis of infertility, aiming to develop better diagnostic tools.

The LeukoStrat CDx FLT3 Mutation Assay can now be used in Japan as the CDx for quizartinib for the treatment of FLT3-ITD positive relapsed or refractory AML.

Resolution is developing its liquid biopsy assay as a companion diagnostic for niraparib in metastatic castration-resistant prostate cancer.

The drug is for first-line maintenance therapy after BRCA-mutated advanced ovarian cancer patients respond to platinum chemo and the test will identify those with BRCA mutations.

The center will use Qiagen Clinical Insight to analyze, interpret, and report molecular screening of cancer patients to help identify targeted therapies and clinical trial options.

Adaptive currently offers a clinical immunosequencing assay for monitoring minimal residual disease in multiple myeloma and acute lymphoblastic leukemia.

The agreement follows a number of other distribution deals Bioké has signed in recent months including ones with Omni Life Science, Syntec, and Namocell.

The high-throughput, scalable BD Cor system for infectious disease diagnostics is now available in Europe with the firm's BD Onclarity HPV assay. 

With RNA sequence data on thousands of individual lung cells, researchers fleshed out new and known cell clusters, before digging into cell state and cellular interaction changes in asthma.

The UK Competition and Markets Authority has announced concerns that the $1.2 billion merger will reduce competition for Illumina and could scrutinize it further.

The San Diego-based firm emerged from stealth mode with a plan to develop technologies to improve the quality and reduce the cost of genetic analysis.

The funding will support development of a test for the Zika virus using Ontera's silicon nanopore-based molecular diagnostics platform.

A UK court determined that Ariosa's licensee infringed upon at least one claim of Illumina's European patent 1 524 321 and upheld the patent's validity.

By comparing viruses in parts of China with or without endemic EBV-associated nasal cancers, researchers narrowed in on two viral variants associated with increased cancer risk.

A new analysis indicates that colorectal cancer metastases arise from a small number of cells before the primary tumor is large enough to be detected clinically.

A small but significant proportion of autism spectrum disorder cases — particularly those occurring in females — appeared to involve biallelic loss-of function or missense mutations.

Last week, GenomeWeb's readers were most interested in the Icahn School of Medicine's new clinical research arm that will help integrate AI into healthcare.

The acquisition will bring to Invitae single-molecule, cell-free DNA analysis technology and enable lower cost NIPS testing.

H.R. 3235, a long time priority for the National Society of Genetic Counselors, would allow CMS to reimburse genetic counselors for counseling Medicare beneficiaries.

Scientists from the UK and China discussed two new NIPTs that include single-gene disorders and a study to estimate disease recurrence risk in families.

Pages

Bioethicists disagree with a research team's decision to allow the return of risk results for adult-onset conditions from a newborn sequencing project, according to Reuters.

Alterations to particular gene may enable the Quechua of Peru to better tolerate high-altitude life, Ars Technica reports.

Nature News reports that additional South Korean researchers have included the names of children on scientific papers when they did not contribute to the work.

In PLOS this week: statistical approach to prioritize rare variant searches, gene expression alterations in chronic obstructive pulmonary disease, and more.